Researchers from Caedo Oncology AS presented the discovery and preclinical characterization of CO-005, a novel anti-CD47 fusion protein being developed for the treatment of lymphoma.
Adcendo ApS has closed an oversubscribed $135 million series B financing round to support its development of first-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need.
Bright Biologics LLC reported the discovery and preclinical evaluation of BB-203, an anti-PD-L1/anti-VEGF bispecific antibody (Ab) being developed for the treatment of cancer.
A team from Nanjing Leads Biolabs Co. Ltd. presented the discovery and preclinical characterization of LBL-042, a novel bispecific antibody designed to simultaneously target PD-1 and LILRB1/2, with the aim of improving immune evasion of tumor microenvironment and potentially overcoming resistance to immuno-oncology therapy.
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, with a 5-year survival rate of 18%. Glypican-3 (GPC3) is a protein with high expression in HCC but not in healthy tissue, making it an interesting target for therapy.
Researchers from Naya Biosciences Inc. and collaborators presented preclinical data on NY-303, a natural killer (NK) cell engager bispecific antibody targeting both GPC3 and NKp46. NKp46 is a cell surface receptor involved in NK cell activation and the elimination of target cancer cells.
Siren Biotechnology Inc. has unveiled its lead asset, SRN-101, for the treatment of high-grade gliomas. The FDA has granted orphan drug and rare pediatric disease designations to SRN-101 for high-grade gliomas and pediatric-type diffuse high-grade gliomas, respectively.
The transcription factor IKZF2 is a marker of highly suppressive regulatory T cells (Tregs). When IKZF2 is degraded, Tregs become effector-like T cells leading to increased antitumor immune response in the tumor microenvironment.
Trogenix Ltd. has emerged from stealth with a focus on treating cancer through viral immunotherapy. The company was founded as a spinout from the University of Edinburgh last year.
RSS
